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OBJECTIVE — To measure ghrelin and energy intake in the laboratory after pioglitazone
treatment.
RESEARCH DESIGN AND METHODS — This was a parallel, three-arm study with 51
obese diabetic subjects randomized to either 1) pioglitazone plus a portion-controlled diet
(PioPC), 2) pioglitazone plus American Diabetes Association (ADA) dietary advice
(PioADA), or 3) metformin plus ADA advice (MetADA). Energy intake and the suppressive
response of a meal on ghrelin were measured at weeks 0 and 16. Mixed models tested if changes
from week 0 to 16 differed by group.
RESULTS — The PioADA group had a signiﬁcantly larger increase (P  0.05) in energy
intake ([adjusted means  SE] 207  53 kcal) compared with the PioPC (50  46 kcal) and
MetADA (52  49 kcal) groups. Change in restraint and disinhibition (variables associated
with eating behavior) mediated weight change. Ghrelin suppression increased in the PioADA
group, which gained weight.
CONCLUSIONS — A portion-controlled diet attenuated the increase in energy intake after
pioglitazone. Ghrelin responded to weight change not pioglitazone exposure.
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T
hiazolidinediones (TZDs) improve
insulinsensitivity(1)andshiftvisceral
fat to subcutaneous fat (2). TZDs are
associated with weight gain (3,4), which
can negatively affect treatment acceptabil-
ity. It is unclear if increased energy intake is
responsibleforTZD-associatedweightgain.
TheeffectofTZDsonghrelinintheabsence
of weight gain is also unclear.
This study tested the effect of piogli-
tazone treatment on 1) energy intake,
measured in the laboratory; 2) ghrelin; 3)
appetite; 4) dietary restraint and disinhi-
bition;and5)foodcravings.Potentialme-
diators of energy intake and weight
change were also examined.
RESEARCH DESIGN AND
METHODS— Participants (51 obese
men and women) aged 35–75 years who
were diagnosed with type 2 diabetes were
enrolled. The study was approved by the
institutional review board, and participants
provided written informed consent. Com-
pletedescriptionsofthestudyaredescribed
elsewhere (5). Participants had not been
previously treated with TZDs and were not
using drugs that affect metabolism or body
weight (e.g., sibutramine).
Treatment arms
Participants were randomly assigned to
one of three treatment groups for the 16-
weekstudy:1)pioglitazoneplusstandard
dietary advice from the American Diabe-
tes Association (ADA) (PioADA); 2)
pioglitazone plus a portion-controlled
diet (PioPC); and 3) an active control
group, metformin plus ADA advice
(MetADA). These treatments have been
previously described (5). Brieﬂy, all par-
ticipants were prescribed a diet that was
500 kcal/day less than their energy re-
quirements. The PioPC group drank
oneGlucerna(290kcal)forbreakfastand
one for lunch, with a planned evening
meal.
Outcome variables
Change from baseline to week 16 (week
16 minus week 0) on the following vari-
ables was quantiﬁed.
Fourhoursaftera371-kcalbreakfast,
energyintakewasmeasuredobjectivelyat
lunch in the laboratory using methods
that produce repeatable/reliable energy
intake measurements (6). Serum ghrelin
levels were measured before and 2 h after
the start of lunch to quantify ghrelin re-
sponse to a meal (postmeal minus pre-
meal). Ratings of hunger, desire to eat,
fullness, and prospective food consump-
tion were measured with visual analog
scales (VASs) (7) before and after lunch.
The eating inventory quantiﬁed dietary
restraint (the intent to restrict energy in-
take) and disinhibition (the tendency to
overeat) (8). The food-craving inventory
(FCI) measured general cravings (total
score) and cravings for the following spe-
ciﬁc types of foods: sweets, high fats, car-
bohydrates/starches, fruits/vegetables,
and fast-food fats (9).
Data analyses
Analyses were conducted with 0.05
using SAS version 9.0 (Cary, NC). Mixed
models tested if change on the outcome
variables differed by group (baseline val-
ues were covariates). Posthocs tested for
differences among the three groups.
Regression methods (10) were used
to test for mediators of differential body
weight change between the PioPC and
PioADA groups. The following possible
mediators were tested: ghrelin, energy in-
take, dietary restraint, and disinhibition.
Pearson correlation coefﬁcients were cal-
culated to determine the amount of vari-
ance in body weight (and energy intake)
change that was accounted for by change
in restraint and disinhibition.
RESULTS— Forty-eight of 51 partici-
pants completed the trial (2 subjects
dropped out from the PioADA and 1
from the MetADA group). As previ-
ously reported (5), PioADA gained
(meansSD)2.151.09kg,MetADA
lost 3.21  0.7 kg, and PioPC lost
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a smaller decrease in visceral fat com-
pared with PioPC group but a larger
increase in deep subcutaneous fat com-
pared with the MetADA group (5).
Baseline characteristics and change in
outcome variables are provided in Table
1.Energyintakeincreasedsigniﬁcantlyin
the PioADA (P  0.001) but not the
MetADA (P  0.30) or PioPC (P 
0.28) groups. Increased energy intake in
the PioADA group was signiﬁcantly
larger than the MetADA and PioPC
groups (P  0.05). The difference in least
squares (LS) means  SE between the
PioADA and MetADA and PioADA
and PioPC groups was 155  73 and
157  70 kcal, respectively.
The PioADA group had a signiﬁ-
cantly larger meal-induced suppression
of ghrelin at week 16 compared with
week 0, which was signiﬁcantly larger
than the nonsigniﬁcant changes in the
MetADA and PioPC groups. The
within-run assay coefﬁcient of variation
was 10%. Change in appetite ratings did
not differ signiﬁcantly among the groups
(datanotshown)(P0.25).ThePioPC
group had a signiﬁcant increase in dietary
restraint and a decrease in disinhibi-
tion and hunger. Change in these end
points differed signiﬁcantly between the
PioPC and PioADA groups (P 
0.01). The difference in LS means  SE
between the PioPC and PioADA
groups on restraint and disinhibition was
4.8  1.4 and 2.5  0.9, respectively.
The MetADA group experienced a sig-
niﬁcant decrease in general cravings and
cravings for high-fat foods. Change in
cravingsdidnotdifferamonggroups(P
0.06).
Change in restraint and disinhibition
mediated differential weight change be-
tweenthePioPCandPioADAgroups.
Mediators of energy intake change were
nonsigniﬁcant. Change in restraint and
disinhibitionwerenegatively(r0.53,
P  0.001) and positively (r  0.39, P 
0.01) associated with change in body
weight, accounting for 28.4 and 15.2% of
body weight change variance, respec-
tively. Change in restraint and disinhibi-
tion were negatively (r  0.44, P 
0.01) and positively (r  0.31, P  0.05)
associated with change in energy intake,
accounting for 19 and 9.3% of energy in-
take change variance, respectively.
CONCLUSIONS — This is the ﬁrst
study to demonstrate that pairing piogli-
tazone treatment with a portion-
controlled diet (PioPC) attenuates
pioglitazone-associated increases in en-
ergy intake. Suppression of ghrelin in re-
sponse to a meal increased only in the
groupwhogainedweight(PioADA),in-
dicating that ghrelin suppression is de-
pendent on body weight change and not
pioglitazone treatment. The results indi-
cate that pioglitazone-associated weight
gain is secondary to increased energy in-
take. Larger increases in restraint and de-
creases in disinhibition were observed in
the PioPC group, with restraint account-
ingfor28.4%ofthevarianceinbodyweight
change. Change in restraint and disinhibi-
tion mediated weight change.
Strengths of the study include the ob-
jective measurement of energy intake in a
controlled study design. Limitations in-
clude measuring energy intake during
Table1—Baseline(week0)participantcharacteristicsandchangeonoutcomevariablesfrom
w e e k0t o1 6
MetADA PioADA PioPC
n 16 14 18
Sex (male/female) 6/10 4/10 6/12
Race (percent white) 62.5 78.5 50
Age (years) 56.9  2.0 59.2  2.5 55.7  2.4
Weight (kg) 97.8  3.8 98.5  3.4 95.3  4.5
BMI (kg/m
2) 36.4  1.7 35.7  1.7 34.3  1.4
Waist circumference (cm)
Men 103  5 109  6 110  7
Women 114  5 113  3 102  4
A1C (percent) 6.0  0.2 6.2  0.2 6.4  0.2
Glucose (mg/dl) 129  6 140  8 135  5
Insulin (U/ml) 18.8  2.0 19.4  1.8 18.8  2.2
Homeostasis model assessment of
insulin resistance 2.73  0.29 2.66  0.22 2.72  0.48
Total energy intake (kcal) 559  80 462  49 509  50
Change from week 0 to week 16 52  49
a 207  53*
b 50  46
a
Ghrelin change after a meal (pg/ml),
week 0 54.2  126.8 102.9  124.6 18.1  91.6
Ghrelin change after a meal (pg/ml),
week 16† 43.7  93.7 172.4  107.2 46.5  112.2
Change from week 0 to week 16 11.4  25.1
a 103.3  27.6*
b 1.9  24.9
a
Eating inventory
Hunger 6.2  1.0 5.9  1.0 6.6  0.8
Change from week 0 to week 16 0.6  0.6
a 0.1  0.64
a 1.4  0.58*
a
Restraint 10.3  0.9 9.0  1.3 9.7  1.2
Change from week 0 to week 16 1.8  0.95
ab 0.8  1.02
a 4.0  0.92*
b
Disinhibition 7.6  1.0 8.4  1.0 8.9  0.9
Change from week 0 to week 16 0.3  0.64
a 0.9  0.68
b 1.5  0.62*
ab
Food-craving inventory
High fats 2.60  0.18 2.10  0.16 2.50  0.12
Change from week 0 to week 16 0.25  0.11*
a 0.19  0.12
a 0.01  0.1
a
Sweets 2.70  0.20 2.30  0.21 2.50  0.17
Change from week 0 to week 16 0.20  0.16
a 0.24  0.17
a 0.25  0.15
a
Carbohydrates/starches 2.60  0.23 2.20  0.16 2.40  0.12
Change from week 0 to week 16 0.17  0.12
a 0.07  0.12
a 0.13  0.11
a
Fast-food fats 2.80  0.23 2.30  0.13 2.40  0.19
Change from week 0 to week 16 0.26  0.14
a 0.22  0.15
a 0.08  0.13
a
Fruits and vegetables 2.80  0.25 2.20  0.24 2.60  0.15
Change from week 0 to week 16 0.20  0.14
a 0.08  0.15
a 0.16  0.13
a
Total score 2.70  0.18 2.20  0.16 2.50  0.10
Change from week 0 to week 16 0.21  0.1*
a 0.15  0.11
a 0.07  0.1
a
Data are means  SE. LS means  SE, which are adjusted for baseline values, depict change on the outcome
variables from week 0 to 16 and are included below the week 0 values. *Change score differed signiﬁcantly
from 0 (P  0.05). Lettered superscripts that differ indicate that those groups’ change scores differed
signiﬁcantly from each other (P  0.05). †The suppression of ghrelin after a meal at week 0 and week 16 is
included in the table.
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treatment. Further research is warranted
to examine the long-term effect of piogli-
tazonetreatmentonenergyandmacronu-
trient intake.
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